BIOPHARM MARKET TO INCREASE FROM $1.4 TO $2.6 BILLION IN '06.

The cell culture industry, which began in the late 1980s from the utilization of recombinant DNA technology and cell hybridization, is now a significant foundation of the biopharmaceutical annual market of $30 Billion. In 2000-2003, regulators in North America and Europe approved a total of 64 biopharmaceuticals for human use. The approved drugs included hormones, blood factors, thrombolytics, vaccines, interferons, monoclonal antibodies (MAb), and therapeutic enzymes. Many of these were produced in mammalian cell culture systems. An estimated 50 new chemical entities were approved in the same period and over a quarter of all new drug approvals were biopharmaceuticals. All of the 64 new biopharmaceuticals approved were protein-based drugs and an increasing number have undergone some form of engineering. The primary method of producing these biopharmaceuticals is mammalian cell culture.

The Large Scale Mammalian Cell Culture Report presents an analysis of currently used techniques in the production of marketed products by mammalian cell culture systems. It presents the latest indications of productivity levels being achieved as well as the latest information on cell culture media, disposable technology, competitor technologies, and capacity issues. The report includes up to date figures of the revenue that products generated by this technology achieve and the companies that market them. Results of an industry technology survey provide primary research on the current opinions of industry practitioners.

The commercial opportunity for this sector is large. The biopharm market is predicted to increase from $1.4 billion in 2003 to $2.6 billion in 2006. The market was dwarfed by the pharmaceutical industry 20 years ago but each year continues to make inroads into its market share. The principle enabler of the biopharm market is mammalian cell culture. Mammalian cell culture is a platform that can be utilized by biotechnology companies, pharmaceutical companies moving into the biopharm space, as well as cell reagent manufacturers and contract manufacturers trying to maintain a competitive edge and meet future trends.

Key Reasons to Purchase

-- Learn about cell culture methods and design such as culture modeling, media selection, and bioreactor design.

-- Learn techniques that are utilized in the production of marketed products by mammalian cell culture systems

-- Receive an overview of the large scale cell culture and mammalian cell culture space.

-- Get expert opinions on the market outlook by reading the analysis of a proprietary survey.

-- Get an inside look into companies active in the cell culture market including their strategic alliances, products and pipelines, financial status, and more.

Questions Answered

-- What is cell culture technology?

-- What are the challenges of utilizing mammalian cells to manufacture drugs?

-- What is the current cell culture industry capacity?

-- What are the trends in outsourcing in this space?

-- What is the impact of PAT on this market?

-- Where are the majority of these products being produced and sold?

-- Who can benefit from cell culture technology?

-- What is the regulatory framework involved in cell culture technology?

Company profiles

-- Abbott Laboratories

-- Amgen

-- Biosynergy (Europe) Ltd 7

-- Boeheringer-Ingelheim

-- Cambrex Biopharmaceutical Services

-- Diosynth Biotechnology

-- DSM Biologics

-- GlaxoSmithKline Biopharmaceuticals

-- HyClone

-- JRH Biosciences

-- Lonza

-- New Brunswick Scientific

-- SAFC

-- Wave Biotechnology

-- Xcellerex

For more information visit http://www.researchandmarkets.com/reports/c24642